scholarly journals PD61-05 RANDOMIZED TRIAL COMPARING URINARY CONTINENCE RATES BETWEEN PELVIC MUSCLES EXERCISES WITH AND WITHOUT TRANS-PELVIC MAGNETIC STIMULATION AFTER ROBOTIC ASSISTED RADICAL PROSTATECTOMY

2021 ◽  
Vol 206 (Supplement 3) ◽  
Author(s):  
Mattia Nicola Sangalli ◽  
Paolo Vota ◽  
Matteo Zanoni ◽  
Giovanni Toia ◽  
Cinzia Mazzieri ◽  
...  
2017 ◽  
Vol 11 (3-4) ◽  
pp. 93 ◽  
Author(s):  
Wan Song ◽  
Chan Kyo Kim ◽  
Byung Kwan Park ◽  
Hwang Gyun Jeon ◽  
Byong Chang Jeong ◽  
...  

Introduction: We sought to investigate the impact of preoperative and postoperative membranous urethral length (MUL) on urinary continence using 3 Tesla (3T) magnetic resonance imaging (MRI) after robotic-assisted radical prostatectomy (RARP).Methods: Between 2008 and 2013, 190 men with RARP underwent preoperative and postoperative MRI. Patients who received adjuvant radiotherapy or who were lost to followup were excluded, leaving 186 patients eligible for analysis. Preoperative MUL was estimated from the prostate apex to the penile bulb, while postoperative MUL was estimated from the bladder neck to penile bulb. Patients with no pads or protection were considered to have complete continence. Logistic regression analysis was used to identify predictors associated with urinary incontinence at six and 12 months.Results: Age was commonly associated with urinary incontinence at six and 12 months. In addition, diabetes mellitus (DM) was another factor associated with urinary incontinence at 12 months. When adjusting these variables, preoperative MUL ≤16 mm (95% confidence interval [CI] 1.01‒1.14; p=0.022), postoperative MUL ≤14 mm (95% CI 1.16‒9.80; p=0.025) and percent change of MUL >18% (95% CI 1.17‒7.23; p=0.021) were significantly associated with urinary incontinence at six months. However, at 12 months, preoperative MUL ≤13.5 mm (95% CI 1.85‒19.21; p=0.003) and postoperative MUL ≤13 mm (95% CI 1.24‒13.84; p=0.021) had impacts on urinary incontinence, but not percent change of MUL.Conclusions: Preoperative and postoperative MUL were significantly associated with urinary continence recovery after RARP. Therefore, efforts to preserve MUL are highly recommended during surgery for optimal continence outcomes after RARP.


2007 ◽  
Vol 177 (4S) ◽  
pp. 491-491
Author(s):  
Thomas J. Mueller ◽  
Daniel G. DaJusta ◽  
Isaac Y. Kim ◽  
Jun Hyuk Hong ◽  
Jonathan J. Hwang

2021 ◽  
Vol 39 (6_suppl) ◽  
pp. TPS262-TPS262
Author(s):  
Eoin Dinneen ◽  
Jack Grierson ◽  
Aiman Haider ◽  
Alex Freeman ◽  
Jonathan Aning ◽  
...  

TPS262 Background: Robot-assisted radical prostatectomy (RARP) offers cure for localised prostate cancer but is associated with considerable toxicity. Potency and urinary continence are improved when the neurovascular bundles (NVBs) are preserved during a nerve-sparing (NS) RARP. The NeuroSAFE (intra-operative frozen section examination of the neurovascular structure adjacent prostate margin) seeks to promote optimal NS to maximise the opportunity for functional recovery without jeopardising oncological safety. The NeuroSAFE technique in RP has never been evaluated against a standard of care in an randomised controlled trial. Methods: This is a pragmatic, multicentre, single-blinded randomised controlled trial (RCT) in which men are allocated in a 1:1 ratio to NeuroSAFE RARP or standard RARP. Men in the NeuroSAFE RARP arm will undergo RARP with NS guided by the NeuroSAFE technique. Men in the standard RARP arm will undergo RARP with NS guided by standard current practice (prostate cancer clinical characteristics, multi-parametric magnetic resonance imaging (mpMRI) recommendations and digital rectal examination (DRE)). Eligible men will have operable localised prostate cancer, will be opting for RARP as primary treatment and will have good baseline erectile function (EF) (as defined by an Internatinoal Index of Erectile Function (IIEF)-5 score >21). The primary outcome is the proportion of men who achieve EF recovery at 12-months according to the IIEF. Oncological safety will be ensured by the independent DMC who will routinely review proportions of men with treatment failure (adjuvant therapy or biochemical recurrence (BCR)) in each arm. A sample size of 404 is estimated required. NeuroSAFE PROOF will continue to follow participant recovery for 5 years following treatment. Key secondary outcomes include patient-reported urinary continence recovery, sexual satisfaction, quality of life, and economic analyses. NeuroSAFE PROOF will be the first RCT of frozen section in radical prostatectomy (RP) in the world. Ethics and dissemination: Ethical approval was obtained from the National Research Ethics Committee North London (17/LO/1978). Results of this study will be disseminated through national and international papers, and to study participants. Clinical trial information: NCT03317990.


2022 ◽  
Vol 48 (1) ◽  
pp. 122-130
Author(s):  
Thiago Camelo Mourão ◽  
Renato Almeida Rosa de Oliveira ◽  
Ricardo de Lima Favaretto ◽  
Thiago Borges Marques Santana ◽  
Carlos Alberto Ricetto Sacomani ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document